Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

This study has been completed.

First Received: September 11, 2005 Last Updated: October 3, 2006 History of Changes

Sponsored by:	Bayside Health
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00163631

Purpose

Investigate vasoactive medicators in portal hypertension on stored sera

Condition
Portal Hypertension

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Retrospective Study
Official Title:	Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

Resource links provided by NLM:

MedlinePlus related topics: Cirrhosis High Blood Pressure

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163631

Locations

Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3181

Sponsors and Collaborators

Bayside Health

Investigators

Principal Investigator:

William W Kemp, MBBS FRACP

The Alfred

More Information

No publications provided

Study ID Numbers:	4104
Study First Received:	September 11, 2005
Last Updated:	October 3, 2006
ClinicalTrials.gov Identifier:	NCT00163631 History of Changes
Health Authority:	Australia: Human Research Ethics Committee

Study placed in the following topic categories:

Liver Diseases
Digestive System Diseases
Fibrosis
Portal Hypertension

Vascular Diseases
Hypertension, Portal
Liver Cirrhosis
Hypertension

Additional relevant MeSH terms:

Liver Diseases
Pathologic Processes
Digestive System Diseases
Fibrosis
Vascular Diseases

Cardiovascular Diseases
Liver Cirrhosis
Hypertension, Portal
Hypertension

ClinicalTrials.gov processed this record on September 11, 2009